JP2012017342A5 - - Google Patents

Download PDF

Info

Publication number
JP2012017342A5
JP2012017342A5 JP2011228229A JP2011228229A JP2012017342A5 JP 2012017342 A5 JP2012017342 A5 JP 2012017342A5 JP 2011228229 A JP2011228229 A JP 2011228229A JP 2011228229 A JP2011228229 A JP 2011228229A JP 2012017342 A5 JP2012017342 A5 JP 2012017342A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
capsular saccharide
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011228229A
Other languages
English (en)
Japanese (ja)
Other versions
JP5314745B2 (ja
JP2012017342A (ja
Filing date
Publication date
Priority claimed from GBGB0220198.6A external-priority patent/GB0220198D0/en
Application filed filed Critical
Publication of JP2012017342A publication Critical patent/JP2012017342A/ja
Publication of JP2012017342A5 publication Critical patent/JP2012017342A5/ja
Application granted granted Critical
Publication of JP5314745B2 publication Critical patent/JP5314745B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2011228229A 2002-08-30 2011-10-17 改変された糖類、それらの結合体、およびそられの製造 Expired - Fee Related JP5314745B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0220198.6A GB0220198D0 (en) 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture
GB0220198.6 2002-08-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004532625A Division JP5268222B2 (ja) 2002-08-30 2003-09-01 改変された糖類、それらの結合体、およびそられの製造

Publications (3)

Publication Number Publication Date
JP2012017342A JP2012017342A (ja) 2012-01-26
JP2012017342A5 true JP2012017342A5 (enExample) 2013-05-30
JP5314745B2 JP5314745B2 (ja) 2013-10-16

Family

ID=9943241

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004532625A Expired - Fee Related JP5268222B2 (ja) 2002-08-30 2003-09-01 改変された糖類、それらの結合体、およびそられの製造
JP2011228229A Expired - Fee Related JP5314745B2 (ja) 2002-08-30 2011-10-17 改変された糖類、それらの結合体、およびそられの製造

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004532625A Expired - Fee Related JP5268222B2 (ja) 2002-08-30 2003-09-01 改変された糖類、それらの結合体、およびそられの製造

Country Status (16)

Country Link
US (2) US8895516B2 (enExample)
EP (1) EP1534342B1 (enExample)
JP (2) JP5268222B2 (enExample)
CN (2) CN1688343B (enExample)
AT (1) ATE319481T1 (enExample)
AU (1) AU2003260921B2 (enExample)
BR (1) BR0314089A (enExample)
CA (1) CA2497167C (enExample)
DE (1) DE60303961T2 (enExample)
DK (1) DK1534342T3 (enExample)
ES (1) ES2260682T3 (enExample)
GB (1) GB0220198D0 (enExample)
MX (1) MXPA05002315A (enExample)
NZ (1) NZ538703A (enExample)
RU (2) RU2005108992A (enExample)
WO (1) WO2004019992A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
PT2172213E (pt) * 2003-01-30 2013-06-03 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
US20070258986A1 (en) * 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
CN101282984B (zh) 2005-05-06 2013-05-08 诺华疫苗与诊断股份有限公司 A型脑膜炎疫苗的免疫原
AR058592A1 (es) * 2005-12-22 2008-02-13 Glaxosmithkline Biolog Sa Vacuna
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
US9475864B2 (en) 2008-09-05 2016-10-25 University Of Massachusetts Methods, compositions and vaccines relating to Neisseria meningitidis antibodies
PT2445522T (pt) 2009-06-22 2017-10-04 Wyeth Llc Composições imunogénicas de antigénios de staphylococcus aureus
EP3461496B1 (en) * 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
CN109134677A (zh) * 2009-10-30 2019-01-04 诺华股份有限公司 金黄色葡萄球菌5型和8型荚膜多糖的纯化
FI3831406T3 (fi) 2010-08-23 2024-08-06 Wyeth Llc Neisseria meningitidis rlp2086 -antigeenien stabiileja formulaatioita
MY166172A (en) 2010-09-10 2018-06-07 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
CA2960030C (en) 2012-03-09 2020-02-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
AU2014316722B2 (en) 2013-09-08 2017-09-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3104886B1 (en) * 2014-02-14 2018-10-17 Pfizer Inc Immunogenic glycoprotein conjugates
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
BR112018068523A2 (pt) * 2016-03-15 2019-01-22 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd novos conjugados de polissacarídeo-proteína e processo para obter os mesmos
DK3506935T3 (en) 2016-09-02 2024-04-02 Sanofi Pasteur Inc Neisseria meningitidis-vaccine
JP7010961B2 (ja) 2017-01-31 2022-02-10 ファイザー・インク 髄膜炎菌組成物およびその方法
KR20240011879A (ko) 2017-02-24 2024-01-26 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체의 면역원성의 증진
CA3074703A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019050816A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
JP7728704B2 (ja) * 2019-03-08 2025-08-25 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 炭素環誘導体及びそれらのコンジュゲート誘導体、並びにワクチンにおけるそれらの使用
AU2020355401B2 (en) 2019-09-27 2025-03-27 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2427341A1 (fr) * 1978-06-02 1979-12-28 Delalande Sa Nouveaux derives aminoglycosidiques hemisynthetiques, leur procede de preparation et leur application en therapeutique
DK0447171T3 (da) * 1990-03-15 1994-12-12 Tanabe Seiyaku Co Polysulfat af cyclodextrinderivat og fremgangsmåde til fremstilling deraf
AU7948494A (en) * 1993-12-28 1995-07-17 Pfizer Inc. Steroidal glycosides
CA2189356A1 (en) 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
JP4290766B2 (ja) * 1997-01-21 2009-07-08 サノフィ・パスツール 多糖―ペプチド複合体
US5929049A (en) * 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
DE69737298T2 (de) * 1997-08-08 2007-06-28 Dade Behring Marburg Gmbh Konjugate von polysacchariden und biomolekülen
US5952454A (en) * 1997-12-12 1999-09-14 The United States Of America As Represented By The Department Of Health And Human Services Linking compounds useful for coupling carbohydrates to amine-containing carriers
BR0308768A (pt) 2002-03-26 2005-02-15 Chiron Srl Sacarìdeos modificados possuindo estabilidade melhorada em água
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture

Similar Documents

Publication Publication Date Title
JP2012017342A5 (enExample)
AU2008227128B2 (en) Conjugates of synthetic TLR agonists and uses therefor
JP2013136639A5 (enExample)
JP2010132925A5 (enExample)
JP2010515718A5 (enExample)
TWI633112B (zh) 醣類-醣脂類結合性疫苗
JP2022068303A (ja) 多価肺炎球菌多糖体-タンパク質複合体組成物
JP2014218516A5 (enExample)
EA023725B1 (ru) Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
JP2007507487A5 (enExample)
JP2008526939A5 (enExample)
RU2007145219A (ru) Иммуногены для вакцин против менингита а
JP2017532321A (ja) 肺炎連鎖球菌血清型8に対するワクチン
CN110302375A (zh) 一种糖缀合物及其用途
Mat Rani et al. Outer membrane vesicles as biomimetic vaccine carriers against infections and cancers
JP6630440B2 (ja) ストレプトコッカス ニューモニアエ(Streptococcus pneumoniae)血清型2に対する合成ワクチン
WO2012145626A1 (en) Synthetic oligosaccharides for staphylococcus vaccine
JP5249041B2 (ja) ビスアシルオキシプロピルシステイン複合体に基づく新規なアジュバント及び誘導体並びに医薬組成物におけるその使用
JP2010528088A5 (enExample)
WO2013178236A1 (en) Carbohydrate-glycolipid conjugate vaccines
JP2008231343A (ja) ワクチン剤
JP2011527340A5 (enExample)
JP2007518732A5 (enExample)
JP2026504779A (ja) ワクチンアジュバントとして有用な化合物および製剤